Source:http://linkedlifedata.com/resource/pubmed/id/10980214
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0007226,
umls-concept:C0008976,
umls-concept:C0012634,
umls-concept:C0022646,
umls-concept:C0022658,
umls-concept:C0085542,
umls-concept:C0118168,
umls-concept:C0681850,
umls-concept:C0730345,
umls-concept:C0814861,
umls-concept:C1442488,
umls-concept:C1521970,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C1707689,
umls-concept:C1708528,
umls-concept:C1801960,
umls-concept:C2349001,
umls-concept:C2697811,
umls-concept:C2699007
|
| pubmed:issue |
6
|
| pubmed:dateCreated |
2000-10-18
|
| pubmed:abstractText |
This study describes the rationale, design, and baseline characteristics of a trial to determine whether treatment with fosinopril 20 mg/day and/or pravastatin 40 mg/ day will prevent cardiovascular and renal disease in nonhypertensive (RR <160/100 mm Hg and not using antihypertensive medication) and nonhypercholesterolemic (total cholesterol <8.0 or <5.0 mmol/L in case of previous myocardial infarction and not using lipid lowering medication) men and women with persistent microalbuminuria (urinary albumin excretion >10 mg/L once in an early morning spot urine and 15 to 300 mg/24-hour at least once in two 24-hour urine collections). The Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a single-center, double-blind, randomized, placebo-controlled trial with a 2 x 2 factorial design. The 864 randomized subjects will be monitored for a minimum of 4 years and a maximum of 5 years. The primary efficacy parameter is defined as the combined incidence of all-cause mortality or hospital admission for documented (1) nonfatal myocardial infarction, (2) myocardial ischemia, (3) heart failure, (4) peripheral vascular disease, (5) cerebrovascular accident and/or (6) end-stage renal disease.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0002-9149
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
86
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
635-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10980214-Adult,
pubmed-meshheading:10980214-Aged,
pubmed-meshheading:10980214-Albuminuria,
pubmed-meshheading:10980214-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:10980214-Blood Pressure,
pubmed-meshheading:10980214-Cardiovascular Diseases,
pubmed-meshheading:10980214-Double-Blind Method,
pubmed-meshheading:10980214-Drug Therapy, Combination,
pubmed-meshheading:10980214-Female,
pubmed-meshheading:10980214-Fosinopril,
pubmed-meshheading:10980214-Humans,
pubmed-meshheading:10980214-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:10980214-Hypercholesterolemia,
pubmed-meshheading:10980214-Kidney Diseases,
pubmed-meshheading:10980214-Male,
pubmed-meshheading:10980214-Middle Aged,
pubmed-meshheading:10980214-Pravastatin,
pubmed-meshheading:10980214-Randomized Controlled Trials as Topic,
pubmed-meshheading:10980214-Research Design
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]).
|
| pubmed:affiliation |
Department of Clinical Pharmacology, University of Groningen, The Netherlands. g.f.h.diercks@med.rug.nl
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|